Is the LDL receptor involved in cortical amyloid protein clearance?

Neurochemical Research

Volumn 31, Issue 6, 2006, Pages 839-847

  Abdulkarim, Yasir ^a   Hameed, Zeyad ^b  

^a ST JOHN'S HOSPITAL   (United Kingdom)

^b St Mary's Orthopaedic Hospital   (Ireland)

Author keywords

Amyloid protein; LDL receptor; Statins

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; APOLIPOPROTEIN C1; APOLIPOPROTEIN E; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR;

3' UNTRANSLATED REGION; ALZHEIMER DISEASE; ASTROCYTE; BLOOD BRAIN BARRIER; CHOLESTEROL BLOOD LEVEL; COGNITION; DRUG RESEARCH; FOLLOW UP; GENE SILENCING; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTHESIS; ISCHEMIC HEART DISEASE; MINI MENTAL STATE EXAMINATION; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR INTRINSIC ACTIVITY; REPORTER GENE; RETROSPECTIVE STUDY; REVIEW; RISK REDUCTION; SENILE PLAQUE; TRANSCYTOSIS; UPREGULATION; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, LDL; RETROSPECTIVE STUDIES;

EID: 33746342465     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-006-9084-0     Document Type: Review

References (57)

1. Kang J, Lemaire H-G, Unterbeck A, Salbaum JM, Masters CL, Grzeschik K-H, Multhaup G, Beyreuther K, Muller-Hill B (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733-736
2. Yoshikai S, Sasaki H, Doh-ura K, Furuya H, Sakaki Y (1990) Genomic organization of the human amyloid beta-protein precursor gene. Gene 87:257-263
3. Kitaguchi N, Takahashi Y, Tokushima Y, Shiojiri S, Ito H (1988) Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity. Nature 331, 530-532;doi:10.1038/331530a0
4. Tanzi RE, McClatchey AI, Lamperti ED, Villa-Komaroff L, Gusella JF, Neve RL (1988) Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. Nature 331:528-532
5. de Sauvage F, Octave JN (1989) A novel mRNA of the A4 amyloid precursor gene coding for a possibly secreted protein. Science Aug 11, 245(4918):651-653
6. Oltersdorf T, Ward PJ, Henriksson T, Beattie EC, Neve R, Lieberburg I, Fritz LC (1990) The Alzheimer amyloid precursor protein. Identification of a stable intermediate in the biosynthetic/degradative pathway. J Biol Chem 265: 4492-4497
7. Sinha S, Dovey HF, Seubert P, Ward PJ, Balcher RW, Blaber M, Bradshaw RA, Arici M, Mobley WC, Lieberburg I (1990)The protease inhibitory properties of the Alzheimer's beta-amyloid precursor protein. J Biol Chem 265:8983-8985
8. Konig G, Monning U, Czech C, Prior R, Banati R, Schreiter-Gasser U, Bauer J, Masters CL, Beyreuther K (1992) Identification and differential expression of a novel alternative splice isoform of the beta A4 amyloid precursor protein (APP) mRNA in leukocytes and brain microglial cells. J Biol Chem 267(15):10804-10809.
9. Estus S, Golde TE, Kunishita T, Blades D, Lowery D, Eisen M, Usiak M, Qu XM, Tabira T, Greenberg BD, (1992a) Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor. Science 255(5045):726-728
10. Estus S, Golde TE, Younkin SG (1992b) Normal processing of the Alzheimer's disease amyloid beta protein precursor generates potentially amyloidogenic carboxyl-terminal derivatives. Ann N Y Acad Sci Dec 31 674:138-148
11. Golde TE, Estus S, Younkin LH, Selkoe DJ, Younkin SG (1992) Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science 255(5045):728-730
12. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schiossmacher M, Whaley J, Swindlehurst C, McCormack R, Wolfert R, Selkoe D, Lieberburg L & Schenk D (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359, 325-327; doi:10.1038/359325a0
13. Glenner GG, Wong CW (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120(3):885-890
14. Checler F (1995) Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. J Neurochem 65: 1431-1444
15. Mudher A, Lovestone S (2002) Alzheimer's disease - do tauists and baptists finally shake hands? Trends Neurosci 25(1):22-26
16. Selkoe DJ (1994) Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol 53(5):438-447
17. Uwe B, Stolt P, Herz J (2004) Functions of lipoprotein receptors in neurons. J Lipid Res 45:403-409
18. Tolleshaug H, Goldstein JL, Schneider WJ, Brown MS (1982) Posttranslational processing of the LDL receptor and its genetic disruption in familial hypercholesterolemia. Cell 30(3):715-724
19. Brown MS, Goldstein JL (1979) Receptor-mediated endocytosis: insights from the lipoprotein receptor system. Proc Natl Acad Sci USA 76(7):3330-3337
20. Endo A, Kuroda M (1976) Citrinin, an inhibitor of cholesterol synthesis. J Antibiot (Tokyo) 29(8):841-843
21. Pavlov OV, Bobryshev YuV, Balabanov YuV, Ashwell K (1995) An in vitro study of the effects of lovastatin on human fetal brain cells. Neurotoxicol Teratol 17(1):31-39
22. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 57: 1439-1443
23. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356: 1627-1631
24. Hajjar I, Schumpert J, Hirth V,Wieland D, Eleazer GP (2002) The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 57: M414-M418
25. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I (2002) Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59: 223-227
26. Zamrini E, McGwin G, Roseman JM (2004) Association between statin use and Alzheimer's disease. Neuroepidemiology 23: 94-98
27. Masse I, Bordet R, Deplanque D, Al Khedr A, Richard F, Libersa C, Pasquier F (2005) Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 76(12):1624-1629
28. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, Wormstall H, Hartmann T, Schulz JB (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomised, placebo-controlled, double-blind trial. Ann Neurol 52: 346-350
29. Hoglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blennow K (2004) Plasma levels of beta-amyloid (1-40), beta-amyloid (1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolaemia after treatment with statins. Arch Neurol 61: 333-337
30. Breitner JCS, Zandi PP, Li G, Rea TG, Psaty BM (2004) Can statins prevent AD, or are they just prescribed less often to those with cognitive disorders?. Neurobiol Aging 25[S2]: 5
31. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360(9346):1623-1630
32. Wolozin B, Brown J 3rd, Theisler C, Silberman S (2004) The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease. CNS Drug Rev 10(2):127-146
33. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC Cache County Study investigators (2005). Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study Arch Gen Psychiatry 62(2):217-224
34. Park IH, Hwang EM, Hong HS, Boo JH, Oh SS, Lee J, Jung MW, Bang OY, Kim SU, Mook-Jung I (2003) Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging 24:637-643
35. Retz W, Thome J, Durany N, Harsanyi A, Retz-Junginger P, Kornhuber J, Riederer P, Rosler M (2001) Potential genetic markers of sporadic Alzheimer's dementia. Psychiatr Genet 11(3):115-122
36. Luedecking-Zimmer E, DeKosky ST, Chen Q, Barmada MM, Kamboh MI (2002) Investigation of oxidized LDL-receptor 1 (OLR1) as the candidate gene for Alzheimer's disease on chromosome 12. Hum Genet 111(4-5):443-451
37. D'IntronoA, Solfrizzi V, Colacicco AM, Capurso C, Torres F, Capurso SA, Capurso A, Panza F (2005) Polymorphisms in the oxidized low-density lipoprotein receptor-1 gene and risk of Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 60(3):280-284
38. Gopalraj RK, Zhu H, Kelly JF, Mendiondo M, Pulliam JF, Bennett DA, Estus S (2005) Genetic association of low density lipoprotein receptor and Alzheimer's disease. Neurobiol Aging 26(1):1-7
39. Bertram L, Parkinson M, Mullin K, Menon R, Blacker D, Tanzi RE (2004) No association between a previously reported OLR1 3′ UTR polymorphism and Alzheimer's disease in a large family sample. J Med Genet 41(4):286-288
40. Papassotiropoulos A, Wollmer MA, Tsolaki M, Brunner F, Molyva D, Lutjohann D, Nitsch RM, Hock C (2005) A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. J Clin Psychiatry 66(7):940-947
41. Shi J, Tian J, Pritchard A, Lendon C, Lambert JC, Iwatsubo T, Mann DM (2006) A 3′-UTR polymorphism in the oxidized LDL receptor 1 gene increases Abeta(40) load as cerebral amyloid angiopathy in Alzheimer's disease. Acta Neuropathol (Berl) 111(1):15-20
42. Cao D, Fukuchi KI, Wan H, Kim H, Li L (2005) Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol Aging
43. Yang DS, Small DH, Seydel U, Smith JD, Hallmayer J, Gandy SE, Martins RN (1999) Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience 90(4):1217-1226
44. Qiu Z, Strickland DK, Hyman BT, Rebeck GW (1999) Alpha2-macroglobulin enhances the clearance of endogenous soluble beta-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons. J Neurochem 73(4):1393-1398
45. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH (2000) Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 106(9):1159-1166
46. Deane R, Wu Z, Zlokovic B (2004a) Beta-peptide clearance through transport across the blood-brain barrier RAGE (Yin) versus LRP (Yang) balance regulates. Alzheimer Amyloid Stroke 35:2628-2631
47. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004b) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron Aug 5, 43(3):333-344
48. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106:1489-1499
49. Rebeck GW, Reiter JS, Strickland DK, Hyman BT (1993) Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 11(4):575-580
50. Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK (1995) LDL receptor related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 82(2):331-340
51. Van Uden E, Mallory M, Veinbergs I, Alford M, Rockenstein E, Masliah E (2002) Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. J Neurosci 122(21):9298-9304
52. Zerbinatti and Bu (2005) LRP and Alzheimer's disease Rev Neurosci. 16(2):123-135. Review
53. Harris-White, Frautschy (2005) Low density lipoprotein receptor-related proteins (LRPs), Alzheimer's and cognition Curr Drug Targets. CNS Neurol Disord 4(5):469-480
54. Kim S, Kim CH, Vaziri ND (2005) Upregulation of hepatic LDL receptor-related protein in nephrotic syndrome: response to statin therapy. Am J Physiol Endocrinol Metab 288(4):E813-817
55. Suzuki H, Yamazaki H, Aoki T, Kojima J, Tamaki T, Sato F, Kitahara M, Saito Y (2000) Lipid-lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits. Arzneimittelforschung 50(11):995-1003
56. Zlokovic B (2005) Neurovascular Mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28(4):202-208
57. Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, Rubio A, Sagare A, Liu D, Li F, Armstrong D, Gasiewicz T, Zidovetzki R, Song X, Hofman F, Zlokovic BV (2005) Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med 11(9):959-965